CADM2 and prostate carcinoma: CADM2 acts as a tumour suppressor in renal cell carcinoma [42], prostate cancer [43] and hepatocellular carcinoma [44], and has been reported promoting brain metastasis in lung cancer and proposed as a potential molecular target [45].